Market Place
Sourcing Support
Argenx Advance Efgartigimod SC in Idiopathic Inflammatory Myopathy
20 Nov 2024 //
GLOBENEWSWIRE
Steritas with Argenx for Steroid-Toxicity Clinical Outcome
19 Nov 2024 //
CONTRACTPHARMA
Argenx & Zai Lab Announce Vyvgart Approval for CIDP in China
11 Nov 2024 //
GLOBENEWSWIRE
argenx to Participate at Upcoming Investor Conferences
05 Nov 2024 //
GLOBENEWSWIRE
Argenx sees early launch success for Vyvgart in CIDP
02 Nov 2024 //
FIERCE PHARMA
Argenx sees early launch success for Vyvgart in CIDP
01 Nov 2024 //
FIERCE PHARMA
argenx Reports Q3 2024 Results & Business Update
31 Oct 2024 //
GLOBENEWSWIRE
argenx Q3 2024 Financial Results on October 31, 2024
24 Oct 2024 //
GLOBENEWSWIRE
Argenx Highlights Data at 2024 Multiple Immunology Programs
15 Oct 2024 //
GLOBENEWSWIRE
Argenx adds 4 new targets to Halozyme collab for $30M
04 Oct 2024 //
FIERCE PHARMA
Argenx Publishes Adhere Study Data In The Lancet Neurology
19 Sep 2024 //
GLOBENEWSWIRE
argenx to Present at Upcoming Investor Conferences
27 Aug 2024 //
GLOBENEWSWIRE
Argenx`s Vyvgart Competes Well With AstraZeneca In Myasthenia Gravis
25 Jul 2024 //
FIERCE PHARMA
Argenx Reports H1 2024 Financials And Q2 Business Update
24 Jul 2024 //
GLOBENEWSWIRE
Argenx `s Biologic Vyvgart (Efgartigimod) Receives Suppl Approvals in US
24 Jul 2024 //
FDA
Argenx To Report H1 2024 Results And Q2 Update On July 25
18 Jul 2024 //
GLOBENEWSWIRE
Zai Lab And Argenx Get China Approval For Efgartigimod In Myasthenia Gravis
16 Jul 2024 //
BUSINESSWIRE
J&J unwraps data on $6.5B autoimmune asset as it crash argenx and UCB`s party
01 Jul 2024 //
FIERCE BIOTECH
Argenx Highlights Autoimmune Pipeline with New Multifocal Motor Neuropathy Data
25 Jun 2024 //
GLOBENEWSWIRE
Argenx snares 2nd US nod for Vyvgart Hytrulo
22 Jun 2024 //
FIERCE PHARMA
Argenx Efgartigimod Alfa & Hyaluronidase-Qvfc Receives Suppl Approval in US
21 Jun 2024 //
FDA
argenx To Unveil `Vision 2030` During Upcoming R&D Day On July 16, 2024
17 Jun 2024 //
GLOBENEWSWIRE
Argenx Drops Post-Covid Program, Mirum Picks Bile Duct Disease Dose
17 Jun 2024 //
ENDPTS
argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference
04 Jun 2024 //
GLOBENEWSWIRE
iTeos to raise $120M; Xbrane and STADA to out-license Lucentis biosimilar
10 May 2024 //
ENDPTS
Argenx isn`t sweating over Vyvgart competitors: exec
10 May 2024 //
FIERCE PHARMA
argenx Reports First Quarter 2024 Financial Results and Provides Business Update
09 May 2024 //
GLOBENEWSWIRE
argenx to Present at BofA Securities 2024 Health Care Conference
07 May 2024 //
GLOBENEWSWIRE
argenx announces results of Annual General Meeting of Shareholders
06 May 2024 //
GLOBENEWSWIRE
argenx To Report Q1 2024 Results, Business Update On May 9
02 May 2024 //
GLOBENEWSWIRE
Argenx gears up to launch Vyvgart in next potential indication
17 Apr 2024 //
FIERCE PHARMA
argenx: VYVGART Drives Transformative Autoimmune Outcomes
15 Apr 2024 //
GLOBENEWSWIRE
argenx Advances Clinical Development of Efgartigimod in Sjogren`s Disease
27 Mar 2024 //
GLOBENEWSWIRE
argenx Announces Approval of VYVGART in Japan for immune Thrombocytopenia
26 Mar 2024 //
GLOBENEWSWIRE
FUJIFILM Diosynth Expands Manufacturing Agreement with Argenx for Efgartigimod
25 Mar 2024 //
PRESS RELEASE
Argenx starts unbranded push ahead of hoped-for label expansion
29 Feb 2024 //
FIERCE PHARMA
Argenx rolls out campaign for rare autoimmune condition as it awaits FDA ruling
28 Feb 2024 //
ENDPTS
argenx to Present at Upcoming Investor Conferences
26 Feb 2024 //
GLOBENEWSWIRE
Argenx to Report Full Year 2023 Financial Results
22 Feb 2024 //
GLOBENEWSWIRE
argenx Announces FDA Acceptance of sBLA with Priority Review for VYVGART
20 Feb 2024 //
GLOBENEWSWIRE
Halozyme Announces argenx Received Approval in Japan for VYVDURA
18 Jan 2024 //
PR NEWSWIRE
argenx Announces Approval of VYVDURA Injection for Generalized Myasthenia Gravis
18 Jan 2024 //
GLOBENEWSWIRE
argenx Highlights 2024 Strategic Priorities
08 Jan 2024 //
GLOBENEWSWIRE
argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Argenx reports another swing and miss for Vyvgart Hytrulo
20 Dec 2023 //
FIERCE PHARMA
argenx Reports Topline Results from ADDRESS Study of Efgartigimod in Pemphigus
19 Dec 2023 //
GLOBENEWSWIRE
Argenx`s Biologic Vyvgart (efgartigimod) Receives Approval in the U.S.
12 Dec 2023 //
FDA
argenx Reports Results from ADVANCE-SC Study of VYVGART Hytrulo
28 Nov 2023 //
GLOBENEWSWIRE
Argenx`s Vyvgart comes up short of placebo in ITP trial
28 Nov 2023 //
FIERCE PHARMA
argenx drug Vyvgart fails PhIII study in autoimmune platelet disease
27 Nov 2023 //
ENDPTS
argenx Announces European Commission Approval of Subcutaneous VYVGART
16 Nov 2023 //
GLOBENEWSWIRE
argenx to Present at Upcoming Investor Conferences
01 Nov 2023 //
GLOBENEWSWIRE
Subcutaneous Vyvgart helps Argenx treat a `broader population`
01 Nov 2023 //
FIERCE PHARMA
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
31 Oct 2023 //
GLOBENEWSWIRE
argenx to Report Third Quarter 2023 Financial Results
24 Oct 2023 //
GLOBENEWSWIRE
argenx Announces VYVGART Authorized for Sale by Health Canada
20 Sep 2023 //
GLOBENEWSWIRE
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod
15 Sep 2023 //
GLOBENEWSWIRE
argenx to Present at Upcoming Investor Conferences
30 Aug 2023 //
GLOBENEWSWIRE
Argenx Reports Half Year 2023 Financial Results
24 Jul 2023 //
YAHOO FINANCE
